ONWARD Medical publishes company deck outlining spinal cord stimulation platforms for spinal cord injury indications
- ONWARD Medical outlined a three-platform spinal cord stimulation strategy spanning external, implantable, and BCI-enabled systems for spinal cord injury.
- ARCEX is cleared in the US and Europe for improving hand sensation and strength in chronic incomplete SCI; pivotal trial showed 90% improved strength or function.
- ARCIM for blood pressure instability targets a TAM of USD 9.3 billion; pivotal study is underway with up to 112 participants across 22 sites.
- ARCIM blood pressure roadmap points to a commercial launch in 2H 2028, following interim analysis, submission, and approval steps.
- Management cited a USD 15 billion-plus addressable market, 10 FDA Breakthrough Device Designations, and more than 150 issued patents.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONWARD Medical NV published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.
